Wellstat Therapeutics Corporation

Wellstat Therapeutics™ Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontier of modern medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases.Wellstat Therapeutics’ focus is in the following fields:- Oncology and Hematology- Metabolic Diseases- NeurologyWellstat Therapeutics Corporation has developed an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials.A visionary team of experienced business professionals and scientists came together to form Wellstat Therapeutics Corporation in order to explore novel discoveries in medicine. A Company founder and the Chief Executive Officer is also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), BioVeris Corporation, Hyperion Catalysis International, Inc. and Wellstat Biologics Corporation. Wellstat Therapeutics Corporation employs dedicated scientists, business professionals and support personnel at its state-of-the-art facility in Gaithersburg, Maryland.

Contact Details: 930 Clopper Road Gaithersburg Maryland 20878 United States of America Tel: 240-631-2500 Fax: 240-683-3793 Email: inquiries@wellstatbiologics.com WWW: www.wellstattherapeutics.com/

Loading...

Recent Publications by Wellstat Therapeutics Corporation:
Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Previously, uridine pro-drug 2',3',5'-tri-O-acetyluridine (PN401) was...	11th January, 2007	Neuroscience Research, Wellstat Therapeutics Corporation, 930 Clopper	Neurobiol Dis. 2006 Dec;24(3):455-65. Epub 2006 Sep 29. DOI Direct Link
Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine. It has been hypothesized that mitochondrial respiratory chain dysfunction...	16th February, 2006	Neuroscience Research, Wellstat Therapeutics, 930 Clopper Road,	Brain Res. 2005 Dec 20;1066(1-2):164-71. Epub 2005 Dec 5. DOI Direct Link
Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Huntington's disease (HD) is associated with decreased activity of...	11th February, 2004	Neuroscience Research, Wellstat Therapeutics Corporation, 930 Clopper	Brain Res. 2003 Dec 19;994(1):44-54.

BioNews Results for Wellstat Therapeutics Corporation:
Sanofi-aventis and Wellstat enter into an agreement	Express Pharma:  Nov 10 2009 12:48PM Matching: wellstat therapeutics
Wellstat Therapeutics and Sanofi-aventis Ink Pact on Novel Therapy for Type II Diabetes	Individual.com:  Oct 28 2009 5:54AM Matching: wellstat therapeutics
Wellstat Therapeutics And Sanofi-aventis Enter Agreement On Novel Therapy For Type II Diabetes	Pharmaceutical Online:  Oct 26 2009 11:48AM Matching: wellstat therapeutics
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement	World Pharma News:  Oct 26 2009 12:41AM Matching: wellstat therapeutics
News and FDA Updates for Sinobiopharma (OCT:SNBP), sanofi-aventis (NYSE:SNY)	Los Angeles Chronicle:  Oct 23 2009 10:47PM Matching: wellstat therapeutics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Wellstat Therapeutics Corporation news.

Wellstat Therapeutics Corporation Patents:
US Patent No.	Title
7605181	Method for the treatment of metabolic disorders
7041659	Compounds for the treatment of metabolic disorders
7012071	Compounds for the treatment of metabolic disorders
6956028	Compositions and methods for treatment of mitochondrial diseases
6946491	Compounds for the treatment of metabolic disorders
→View more Wellstat Therapeutics Corporation patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1679 times since April 2007, the link to the organisation's website has been followed 241 times

Recent Search Terms used to find this page: Wellstat Therapeutics CMO | Wellstat Therapeutics small molecule | wellstat therapeutics CEO | Wellstat ceo | Wellstat Therapeutics Small-molecule | wellstat therapeutics personnel | Wellstat Therapeutics home page | wellstat therapeutics pipeline | wellstat therapeutics | wellstat therapeutics | .

Search for more companies in Gaithersburg

Search for more companies in Maryland

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Wellstat Therapeutics Corporation